COVID-19 vaccine hesitancy and perceived post-vaccination adverse event: Findings from a cross-sectional survey

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2025-07-20 DOI:10.1016/j.vaccine.2025.127529

Maude Dionne , Chantal Sauvageau , Jeremy K. Ward , Jérémie Sylvain-Morneau , Fátima Gauna , Radhouene Doggui , Ève Dubé

{"title":"COVID-19 vaccine hesitancy and perceived post-vaccination adverse event: Findings from a cross-sectional survey","authors":"Maude Dionne , Chantal Sauvageau , Jeremy K. Ward , Jérémie Sylvain-Morneau , Fátima Gauna , Radhouene Doggui , Ève Dubé","doi":"10.1016/j.vaccine.2025.127529","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>In Quebec, COVID-19 vaccine uptake among adults was high for the first two doses but decreased for the subsequent booster doses. This study assesses the relationships between attitudes towards vaccination and self-reported experience and severity of adverse events following immunization (AEFIs).</div></div><div><h3>Methods</h3><div>A web survey of Quebec adults who received at least one dose of the COVID-19 vaccine was conducted in September 2023. Participants share their level of vaccine hesitancy before vaccination and their experience with AEFIs after receiving a dose. Participants were asked to note the severity of the symptoms they believed were due to vaccination. Intention to receive other vaccines in the future was questioned. Two coders performed a qualitative content analysis on reported AEFIs (<em>N</em> = 3808). Descriptive and multivariate logistic regression analyses were performed.</div></div><div><h3>Results</h3><div>Among the 8419 vaccinated respondents, 46.7 % reported having experienced AEFIs. Fatigue or malaise (20.7 %), injection site disorder (17.3 %), musculoskeletal pain (11.2 %), headache (11.0 %), and fever (10.6 %) were the most commonly reported, respectively. Respondents who were very hesitant before the COVID-19 vaccine reported more frequently having a severe AEFI compared to those who were not hesitant (25.0 % vs 3.4 % =, <em>p</em> < 0.001). This affirmation stays true when all severity of adverse events are considered (68.7 % vs 36.9 %) (<em>p</em> < 0.001). Younger age (aOR = 0.98), being a female (aOR = 1.31), a higher education level (University degree aOR = 1.56 vs high school or less), being vaccine-hesitant in general (aOR = 1.69 vs non or less hesitant) were significantly associated (<em>p</em> < 0.001) with self-reported AEFIs in multivariate analysis. Self-reported AEFIs that prevented doing activities (aOR = 4.87) and being vaccine-hesitant in general (aOR = 4.94) were significantly associated with reduced intention to receive other vaccines in the future.</div></div><div><h3>Conclusion</h3><div>Vaccine hesitancy could influence self-reported AEFIs and their perceived severity. Transparent and tailored communication explaining AEFIs while emphasizing strategies to mitigate these effects could helpful. Our findings also have implications for pharmacovigilance.</div><div>301 mots.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"62 ","pages":"Article 127529"},"PeriodicalIF":4.5000,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25008266","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

In Quebec, COVID-19 vaccine uptake among adults was high for the first two doses but decreased for the subsequent booster doses. This study assesses the relationships between attitudes towards vaccination and self-reported experience and severity of adverse events following immunization (AEFIs).

Methods

A web survey of Quebec adults who received at least one dose of the COVID-19 vaccine was conducted in September 2023. Participants share their level of vaccine hesitancy before vaccination and their experience with AEFIs after receiving a dose. Participants were asked to note the severity of the symptoms they believed were due to vaccination. Intention to receive other vaccines in the future was questioned. Two coders performed a qualitative content analysis on reported AEFIs (N = 3808). Descriptive and multivariate logistic regression analyses were performed.

Results

Among the 8419 vaccinated respondents, 46.7 % reported having experienced AEFIs. Fatigue or malaise (20.7 %), injection site disorder (17.3 %), musculoskeletal pain (11.2 %), headache (11.0 %), and fever (10.6 %) were the most commonly reported, respectively. Respondents who were very hesitant before the COVID-19 vaccine reported more frequently having a severe AEFI compared to those who were not hesitant (25.0 % vs 3.4 % =, p < 0.001). This affirmation stays true when all severity of adverse events are considered (68.7 % vs 36.9 %) (p < 0.001). Younger age (aOR = 0.98), being a female (aOR = 1.31), a higher education level (University degree aOR = 1.56 vs high school or less), being vaccine-hesitant in general (aOR = 1.69 vs non or less hesitant) were significantly associated (p < 0.001) with self-reported AEFIs in multivariate analysis. Self-reported AEFIs that prevented doing activities (aOR = 4.87) and being vaccine-hesitant in general (aOR = 4.94) were significantly associated with reduced intention to receive other vaccines in the future.

Conclusion

Vaccine hesitancy could influence self-reported AEFIs and their perceived severity. Transparent and tailored communication explaining AEFIs while emphasizing strategies to mitigate these effects could helpful. Our findings also have implications for pharmacovigilance.

301 mots.

查看原文本刊更多论文

COVID-19疫苗犹豫和疫苗接种后感知的不良事件：来自横断面调查的结果

在魁北克省，成人的COVID-19疫苗吸收率在前两剂中很高，但在随后的加强剂中下降。本研究评估了对疫苗接种的态度与自我报告的经历和免疫后不良事件严重程度之间的关系。方法对魁北克省于2023年9月接种过至少一剂COVID-19疫苗的成年人进行网络调查。参与者分享了他们在接种疫苗前对疫苗的犹豫程度，以及他们在接种一剂疫苗后对aefi的经历。参与者被要求记下他们认为是由于接种疫苗引起的症状的严重程度。今后是否有意接种其他疫苗受到质疑。两名编码器对报告的aefi进行定性内容分析（N = 3808）。进行描述性和多变量逻辑回归分析。结果在8419名接种疫苗的应答者中，46.7%的人报告经历过急性免疫刺激。疲劳或不适（20.7%）、注射部位紊乱（17.3%）、肌肉骨骼疼痛（11.2%）、头痛（11.0%）和发烧（10.6%）分别是最常见的报告。与不犹豫的受访者相比，在接种COVID-19疫苗前非常犹豫的受访者报告出现严重AEFI的频率更高(25.0% vs 3.4% =, p <；0.001)。考虑到所有不良事件的严重程度，这一结论仍然成立（68.7% vs 36.9%） (p <；0.001)。年龄较小（aOR = 0.98）、女性（aOR = 1.31）、教育程度较高（大学学历aOR = 1.56 vs高中以下）、一般疫苗犹豫（aOR = 1.69 vs非犹豫或较不犹豫）显著相关(p <；在多变量分析中，0.001)与自我报告的aefi。自我报告的aefi阻止了活动（aOR = 4.87）和一般的疫苗犹豫（aOR = 4.94）与未来接种其他疫苗的意愿降低显著相关。结论疫苗犹豫可影响自述的急性呼吸障碍及其感知的严重程度。透明和有针对性的沟通有助于解释aefi，同时强调减轻这些影响的战略。我们的发现对药物警戒也有启示。301著。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.